LATAM MedTech Insights: Pure Global's Guide to Brazil's 30-Day ANVISA Approval for Class II SaMD

Brazil's MedTech market is one of the largest in Latin America, but its regulatory landscape, governed by ANVISA, can seem complex. Many SaMD companies overestimate the time and difficulty of market entry, missing out on significant opportunities. This episode demystifies the process for Class II Software as a Medical Device. We reveal the streamlined 'notificação' pathway, a simplified notification process that can lead to market approval in as little as 30 days. We walk through a real-world example of a dermatology AI app, detailing how proper preparation of the technical dossier and leveraging local expertise led to a rapid and successful market launch, avoiding common delays that can stall companies for months. What you'll learn in this episode: - What is the difference between ANVISA's 'notificação' and 'registro' pathways? - How can a Class II SaMD be approved in under 30 days in Brazil? - What are the essential documents required for a successful SaMD submission? - Why is a Brazil Registration Holder (BRH) mandatory for foreign companies? - What are the most common mistakes that cause delays in ANVISA's review? - How does regulation RDC 751/2022 impact your device classification? - What specific cybersecurity information does ANVISA expect for a SaMD? At Pure Global, we specialize in transforming complex regulatory challenges into clear, actionable market access strategies. With our end-to-end solutions combining local expertise in over 30 countries and advanced AI tools, we help MedTech and IVD companies accelerate their global expansion. Contact us to streamline your entry into the LATAM market. Email us at [email protected] or visit us at https://pureglobal.com/.